Too many possibilities but a few real outcomes.... First, before the na-sayers and bashers come out, know that I have followed this stock long before most of you (check the thread postings 6 months ago and then a year ago).
July 2013- Where will we be? Of course there is no way to actually know... to many possible outcomes to make an assertive claim but what we can do is look at the stock's previous price trend. If this May-July is anything like last May-July where the price advanced from a low of .15 to a peak of .30, then one could argue this could be between .50 and .60 by mid-July 2013. So then what? Well if we look at July 2012 or October 2012 we will see heavy pumping & dumping which could lead the price to retrace 20%-40%. Of course this opens the door for the longs to pick up additional shares for the long haul if they want.
Sept -Oct 2013 - What now? Final results & FDA meeting are completed. Now the investors have what they need to make a more informed decision. Is this really a strong stock? Does it have the potential to compete in the big leagues with it's competitors? Whatever the outcome I would not be shocked to see the pps move from the retraced low in July to a new high in anticipation of good news like we saw in October of 2012. Could this test the technical support of $1.00 or $1.25 or even $1.50... Maybe.
Dec 2013 - Preparation time for Phase IIB trials.... Big step. One concerning piece of information (based on the information available today), it is a scary word - some would even say vulgar word - DILUTION. Why you ask? Well unless a partnership or buyout is announced (which they could in all fairness be announced) then to fund the PHASE IIB trials ONCS will need additional capital and a lot of it. Current burn rate based on recent SEC filing puts them at a $1.4 mil quarterly burn rate with the final installments to INO due later this year.
This is an opinion, NOT A RECOMMENDATION or ADVICE. Conduct your own due diligence and research.
Are you that stupid? Do you think other developmental phase pharma had their pps spike due to revenue too? the word "developmental" means all thing pre-FDA finals, they were all years before any product hitting the market, yet one positive catalyst after another bring up their pps to new height, just like ONCS with these expected milestone AND unexpected rumors/announcement that will take its pps to new height.
THE future of ONCS is always pictured as "ROSY" but it never happens! the "CARROT STICK" is always ahead of the "facts", like a dog CHASING A BONE ON THAT IS ATTACHED TO HIS HARNESS AND STICKS OUT JUST AHEAD OF THE NOSE OF THE DOG!!!!
EVERY STEP NEVER BRINGS THE DOG ANY CLOSER TO THE PRIZE!!!THE PRIZE IS ALWAYS "JUST AHEAD"!!! US SUCKERS, ALL WHO INVEST IN THIS "BONE",WILL NEVER GRAB AND OBTAIN THE "PRIZE" BECAUSE IT IS NOT REAL!! I HAVE REDUCED MY PLANNED INVESTMENT SO I WILL NOT BE HURT WHE IT CHASHES OR THE "DOG" DIES!!
DO AS YOU WISH BUT PLEASE DO NOT BEAT THE "DOG" BECAUSE HE CANNOT CATCH THE "PRIZE"
slamman, nice to see you back posting....it's been a while. Good post! I am more interested in where ONCS will be at then end of Sept. By that time we will have 4 sets of data released. If they are bad, I don't think it will matter where they are in 12 months. BUT, if they are good, then that opens up the real possibility of a good meeting with the FDA. So, I think the end of Sept, early Oct time frame is the real key.
Yes Twiz that is the key. The only thing I worry about is their previous trial sizes. On the IL-12 side, up to now, it showing superiority over Amgen's drug TVEC & Vical's drug Allovectin. This statement says it all for me from SA; "Based on its durability, cost and treatment cycle, treatment of skin cancer through OncoSec's ImmunoPulse therapy is a superior option compared to Amgen's TVEC." This is why I'm in with this many shares...
Sentiment: Strong Buy